Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers.
作者信息
Dayer P, Kubli A, Kupfer A, Courvoisier F, Balant L, Fabre J
出版信息
Br J Clin Pharmacol. 1982 May;13(5):750-2. doi: 10.1111/j.1365-2125.1982.tb01453.x.
Abstract
摘要
相似文献
1
Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers.布呋洛尔羟化缺陷与药物在代谢缓慢者中的副作用相关。
Br J Clin Pharmacol. 1982 May;13(5):750-2. doi: 10.1111/j.1365-2125.1982.tb01453.x.
2
The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.药物氧化两种常见多态性的分子机制——催化布呋洛尔和美芬妥因氧化的细胞色素P-450同工酶功能改变的证据
Xenobiotica. 1986 May;16(5):449-64. doi: 10.3109/00498258609050251.
3
[Pharmacokinetic and clinical consequences of the genetic polymorphism of oxidation].
Schweiz Med Wochenschr. 1983 Feb 26;113(8):295-7.
4
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.β-肾上腺素能受体拮抗剂的多态性氧化。临床药代动力学考量。
Clin Pharmacokinet. 1986 Jan-Feb;11(1):1-17. doi: 10.2165/00003088-198611010-00001.
5
The genetic control of bufuralol metabolism in man.
Eur J Drug Metab Pharmacokinet. 1982 Jan-Mar;7(1):73-7. doi: 10.1007/BF03189547.
6
Polymorphic metabolism of beta-adrenoceptor antagonists.β-肾上腺素受体拮抗剂的多态性代谢
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):11S-19S. doi: 10.1111/j.1365-2125.1984.tb02423.x.
7
Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.人肝微粒体中细胞色素P450 2D6和1A2酶对布呋洛尔的羟基化作用。
Mol Pharmacol. 1994 Sep;46(3):568-77.
8
Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.氧化多态性（异喹胍/鹰爪豆碱型）对布呋洛尔肝首过代谢的影响。
Eur J Clin Pharmacol. 1985;28(3):317-20. doi: 10.1007/BF00543330.
9
Kinetics and metabolism of (+)-, (-)- and (+/-)-bufuralol.（+）-、（-）-和（±）-布呋洛尔的动力学与代谢
Eur J Clin Pharmacol. 1982;23(6):529-33. doi: 10.1007/BF00637501.
10
引用本文的文献
1
Clinical significance of genetic influences on cardiovascular drug metabolism.基因对心血管药物代谢影响的临床意义。
Cardiovasc Drugs Ther. 1993 Jun;7(3):311-24. doi: 10.1007/BF00880154.
2
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.异喹胍氧化表型与普萘洛尔的药代动力学和药效学之间的关系。
Br J Clin Pharmacol. 1984 Jun;17(6):679-85. doi: 10.1111/j.1365-2125.1984.tb02403.x.
3
Polymorphic metabolism of beta-adrenoceptor antagonists.β-肾上腺素受体拮抗剂的多态性代谢
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):11S-19S. doi: 10.1111/j.1365-2125.1984.tb02423.x.
4
Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents.
Eur J Clin Pharmacol. 1983;24(6):797-9. doi: 10.1007/BF00607090.
5
The genetic control of bufuralol metabolism in man.
Eur J Drug Metab Pharmacokinet. 1982 Jan-Mar;7(1):73-7. doi: 10.1007/BF03189547.
6
Phenotyping polymorphic drug metabolism in the French Caucasian population.对法国白种人群中多态性药物代谢进行表型分析。
Eur J Clin Pharmacol. 1988;35(2):167-71. doi: 10.1007/BF00609247.
7
Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.人体肝脏氧化的立体选择性和区域选择性——去甲异喹胍/鹰爪豆碱表型对丁呋洛尔羟基化作用的影响
Eur J Clin Pharmacol. 1986;31(3):313-8. doi: 10.1007/BF00981130.
8
Pharmacodynamic and pharmacokinetic studies on bufuralol in man.布呋洛尔在人体中的药效学和药代动力学研究。
Br J Clin Pharmacol. 1986 Nov;22(5):527-34. doi: 10.1111/j.1365-2125.1986.tb02931.x.
9
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.β-肾上腺素能受体拮抗剂的多态性氧化。临床药代动力学考量。
Clin Pharmacokinet. 1986 Jan-Feb;11(1):1-17. doi: 10.2165/00003088-198611010-00001.
10
Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance.β-肾上腺素能受体阻断药物的多态性代谢及其临床意义。
Eur J Clin Pharmacol. 1985;28 Suppl:77-84. doi: 10.1007/BF00543715.
本文引用的文献
1
Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.调控异喹胍氧化的DH/DL等位基因对苯妥英羟化作用的影响。
Clin Pharmacol Ther. 1981 Apr;29(4):493-7. doi: 10.1038/clpt.1981.68.
2
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.对英国白人人群中异喹胍氧化遗传多态性的家系及群体研究。
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
3
Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.司巴丁N-氧化缺陷与异喹胍4-羟化的药物遗传学共变。
Eur J Clin Pharmacol. 1980 Feb;17(2):153-5. doi: 10.1007/BF00562624.
4
Determination of bufuralol and its major metabolites in plasma by high-performance liquid chromatography.采用高效液相色谱法测定血浆中布呋洛尔及其主要代谢产物。
J Chromatogr. 1980 Dec 12;221(2):327-35. doi: 10.1016/s0378-4347(00)84318-2.
5
Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.人体肝脏中去甲丙咪嗪4-羟化酶缺陷的证据。
Br J Clin Pharmacol. 1981 Jan;11(1):89-91. doi: 10.1111/j.1365-2125.1981.tb01108.x.
6
Influence of renal failure on the hepatic clearance of bufuralol in man.肾衰竭对人体中布呋洛尔肝清除率的影响。
J Pharmacokinet Biopharm. 1980 Oct;8(5):421-38. doi: 10.1007/BF01059544.
7
Determined of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detection.
Biomed Mass Spectrom. 1976 Dec;3(6):281-5. doi: 10.1002/bms.1200030606.
8
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.人司巴丁N-氧化缺陷：一种新的药物遗传学缺陷。
Eur J Clin Pharmacol. 1979 Sep;16(3):183-7. doi: 10.1007/BF00562059.
9
Polymorphism of carbon oxidation of drugs and clinical implications.药物碳氧化的多态性及其临床意义。
Br Med J. 1978 Sep 2;2(6138):655-7. doi: 10.1136/bmj.2.6138.655.
10
Polymorphic hydroxylation of Debrisoquine in man.人对异喹胍的多态性羟基化作用。
Lancet. 1977 Sep 17;2(8038):584-6. doi: 10.1016/s0140-6736(77)91430-1.
Zotero 插件